No Prescription |
 |
 | ||
|
Telnase Azmacort |
|
| ||
No Prescription » Prescription Drugs 15 » Telnase Azmacort IndicationsTelnase is indicated for the treatment and prophylaxis of seasonal and perennial allergic rhinitis in adults and children over 6 years of age.Dosage and AdministrationTelnase is for nasal administration only and should be used regularly for optimal efficacy.In some patients an improvement of symptoms may be apparent within the first day of treatment. However several days of treatment may be needed for optimal benefit to be achieved.Adults and children aged 12 years and over:The recommended starting dose is 220 micrograms as two sprays in each nostril once daily. Once symptoms are controlled patients may be maintained on 110 micrograms as one spray in each nostril once daily.Children aged 6 to 12 years:The maximum recommended dose is 110 micrograms as one spray in each nostril once daily. In patients with more severe symptoms a dose of 220 micrograms may be used. Once symptoms are controlled patients should be maintained on the lowest effective dose.Children under 6 years of age:The safety and efficacy of Telnase in children under 6 years of age have not been established therefore use in this group of patients is currently not recommended. Buy Telnase Azmacort and other Prescription Drugs 15 products online at Medstore. Buy Online at Medstore - Click Here!
About Telnase Azmacort: Product Type: Prescription Drugs 15 Telnase ( Azmacort Nasocort Generic Triamcinolone ) Telnase (Azmacort Nasocort Generic Triamcinolone) Azmacort Nasocort Generic Triamcinolone 55mcg Azmacort Nasocort Generic Triamcinolone Telnase
View more Prescription Drugs 15 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
